Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test catch lung cancer earlier in smokers with COPD?

NCT ID NCT02500693

Diagnosis Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a blood test for circulating tumor cells (CTCs) can help detect lung cancer earlier in people at very high risk: smokers and ex-smokers with COPD. Researchers combined this blood test with low-dose CT scans over three yearly screenings in 683 participants. The goal was to see if CTCs could reduce false positives and catch cancers that CT scans might miss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Isolation of circulating tumor cells (CTC) from blood
What this could lead to
If successful, this approach could improve early lung cancer detection in high-risk COPD patients, reducing false positives and missed cancers from CT scans alone.
What could go wrong
This is a completed observational study, not a treatment trial. The CTC test may not prove reliable enough for routine screening, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

683 people

The number who actually took part.

Started

Oct 2015

Finished

Oct 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 55 years or more * 30 or more pack-years of cigarette smoking history * Former smokers: quit smoking within the previous 15 years * Signed informed consent form * Presence of COPD * Affiliation to the French social security system Exclusion Criteria: * Chest CT examination in the 12 months prior to eligibility assessment(1) * Treatment for, or evidence of, any cancer other than skin basocellular carcinoma in the 5 years prior to eligibility assessment * Pneumonia or acute respiratory infection treated with antibiotics in the 12 weeks prior to eligibility assessment * Unexplained weight loss of more than 15 10%pounds in the 12 months prior to eligibility assessment * Recent hemoptysis * History of lung volume reduction with coils, glue or valves° * Metallic implants or devices in the chest or back, such as pacemakers or Harrington fixation rods * Participation in another cancer screening trial * Participation in a cancer prevention study, other than a smoking cessation study * Vulnerable persons: adults under guardianship, adults under trusteeship or persons deprived of their liberty, patients under 18 years old * Medical and/or psychiatric problems of sufficient severity to limit full compliance with the study or expose patients to undue risk 1. Many COPD patients will have had a previous chest CT examination. This has become common in medical practice, especially in patients with chronic lung diseases such as COPD patients. Including such patients would introduce huge bias in the study by artificially focusing on rapidly growing cancers. Redoing a CT in a screening intend in a patient who recently underwent this investigation would also unnecessarily enhance irradiation in these patients. It should be note that in the NLST trial "previous chest CT (≤ 18 months)" was a key exclusion criterion \[NLST Radiology 2011\].

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset lung neoplasm lung cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung neoplasms Pulmonary disease, chronic obstructive

Contacts and locations

Locations

  • CH de Roubaix

    Roubaix, France

  • CHRU de Lille

    Lille, France

  • CHU d'Amiens

    Amiens, France

  • CHU de Dijon

    Dijon, France

  • CHU de Grenoble

    Grenoble, France

  • CHU de Montpellier

    Montpellier, France

  • CHU de Nancy

    Nancy, France

  • CHU de Reims

    Reims, France

  • CHU de Rennes

    Rennes, France

  • CHU de Rouen

    Rouen, France

  • CHU de Saint Etienne

    Saint-Etienne, France

  • CHU de Strasbourg

    Strasbourg, France

  • CHU de Toulouse

    Toulouse, France

  • CHU de Tours

    Tours, France

  • Hospices Civils de Lyon

    Lyon, France

  • Hôpital Bichat

    Paris, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Européen Georges Pompidou

    Paris, France

  • Hôpital Nord

    Marseille, France

  • Hôpital TENON

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.